JP2007520488A - クエチアピン抗精神病薬による精神病の治療 - Google Patents
クエチアピン抗精神病薬による精神病の治療 Download PDFInfo
- Publication number
- JP2007520488A JP2007520488A JP2006550998A JP2006550998A JP2007520488A JP 2007520488 A JP2007520488 A JP 2007520488A JP 2006550998 A JP2006550998 A JP 2006550998A JP 2006550998 A JP2006550998 A JP 2006550998A JP 2007520488 A JP2007520488 A JP 2007520488A
- Authority
- JP
- Japan
- Prior art keywords
- quetiapine
- patient
- bipolar
- pharmaceutically acceptable
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004431 quetiapine Drugs 0.000 title claims description 38
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title claims description 38
- 239000000164 antipsychotic agent Substances 0.000 title description 4
- 229940005529 antipsychotics Drugs 0.000 title description 3
- 208000028017 Psychotic disease Diseases 0.000 title 1
- 208000020925 Bipolar disease Diseases 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 32
- 208000024891 symptom Diseases 0.000 claims abstract description 19
- 206010026749 Mania Diseases 0.000 claims description 15
- 208000019022 Mood disease Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical group [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 claims description 11
- 229960005197 quetiapine fumarate Drugs 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 206010054089 Depressive symptom Diseases 0.000 claims description 5
- 230000003860 sleep quality Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- VRHJBWUIWQOFLF-WLHGVMLRSA-N 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 VRHJBWUIWQOFLF-WLHGVMLRSA-N 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 description 17
- 208000025307 bipolar depression Diseases 0.000 description 17
- 208000020401 Depressive disease Diseases 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 239000000902 placebo Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000009097 single-agent therapy Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 208000024714 major depressive disease Diseases 0.000 description 4
- 206010002869 Anxiety symptoms Diseases 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000001786 gonorrhea Diseases 0.000 description 3
- 208000027776 Extrapyramidal disease Diseases 0.000 description 2
- 206010021030 Hypomania Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- CAQZTSCRGMRSHX-TYYBGVCCSA-N (e)-but-2-enedioic acid;ethanol Chemical compound CCO.OC(=O)\C=C\C(O)=O CAQZTSCRGMRSHX-TYYBGVCCSA-N 0.000 description 1
- -1 4-dibenzo [b, f] [1,4] thiazepine-11-yl-1-piperazinyl Chemical group 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- YAZBBWJDISBOAL-UHFFFAOYSA-N benzo[d][1,2]benzothiazepine Chemical compound S1N=CC2=CC=CC=C2C2=CC=CC=C12 YAZBBWJDISBOAL-UHFFFAOYSA-N 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000008509 dibenzothiazepines Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54061804P | 2004-01-30 | 2004-01-30 | |
| PCT/SE2005/000094 WO2005072742A1 (en) | 2004-01-30 | 2005-01-27 | Treatment of psychoses with quetiapine antipsychotic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007520488A true JP2007520488A (ja) | 2007-07-26 |
| JP2007520488A5 JP2007520488A5 (enExample) | 2008-03-21 |
Family
ID=34826230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006550998A Pending JP2007520488A (ja) | 2004-01-30 | 2005-01-27 | クエチアピン抗精神病薬による精神病の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20050171088A1 (enExample) |
| EP (1) | EP1713488A1 (enExample) |
| JP (1) | JP2007520488A (enExample) |
| KR (1) | KR20070011276A (enExample) |
| CN (1) | CN1913902A (enExample) |
| AU (1) | AU2005209142A1 (enExample) |
| BR (1) | BRPI0507086A (enExample) |
| CA (1) | CA2495361A1 (enExample) |
| IL (1) | IL176999A0 (enExample) |
| NO (1) | NO20063856L (enExample) |
| RU (1) | RU2006130687A (enExample) |
| WO (1) | WO2005072742A1 (enExample) |
| ZA (1) | ZA200606128B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| WO2006073360A1 (en) * | 2005-01-07 | 2006-07-13 | Astrazeneca Ab | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
| TW200735878A (en) * | 2005-11-18 | 2007-10-01 | Astrazeneca Ab | Pharmaceutical compositions |
| US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
| WO2008079848A1 (en) * | 2006-12-20 | 2008-07-03 | Astrazeneca Ab (Se/Se) | Compounds and uses thereof |
| CN101528698A (zh) | 2006-05-09 | 2009-09-09 | 阿斯利康公司 | (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式 |
| TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| US8682445B2 (en) * | 2006-07-28 | 2014-03-25 | Cyberonics, Inc. | Patient management system for treating depression using an implantable medical device |
| EP2519101B1 (en) | 2009-12-31 | 2015-08-19 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| SI2544536T1 (sl) | 2010-03-11 | 2019-03-29 | Kempharm, Inc. | Maščobno kislinski konjugati kvetiapina proces za njih izdelavo in uporabo |
| JP2013528601A (ja) | 2010-05-20 | 2013-07-11 | アストラゼネカ・アクチエボラーグ | アリール置換オレフィン系アミンの新規な製造方法 |
| CN102631350B (zh) * | 2012-03-29 | 2013-10-16 | 南京正科制药有限公司 | 一种富马酸喹硫平与鲁拉西酮的复方制剂 |
| CN102716133A (zh) * | 2012-04-06 | 2012-10-10 | 中国人民解放军第三军医大学 | 喹硫平在制备预防和治疗自身免疫性疾病的药物中的应用 |
| CN109464451B (zh) * | 2019-01-15 | 2021-07-13 | 范崇桂 | 一种治疗神经衰弱的药物及其制备方法 |
| RU2717939C1 (ru) * | 2019-10-29 | 2020-03-27 | Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе | Способ лечения интоксикационных психозов при острых отравлениях психоактивными веществами |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US6622036B1 (en) * | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| CA2328197C (en) * | 1998-04-14 | 2007-11-20 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| US20030027817A1 (en) * | 1998-05-29 | 2003-02-06 | Tollefson Gary Dennis | Combination therapy for treatment of bipolar disorders |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6194466B1 (en) * | 1998-10-15 | 2001-02-27 | Elizabeth Marie Cottingham | Use of metformin to counteract weight gain associated with valproate and other psychotropic medications |
| US20030096808A1 (en) * | 1999-03-29 | 2003-05-22 | Jon M. Miller | Substance to prevent or reverse weight gain induced by psychoactive agents |
| US6489341B1 (en) * | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
| US6350773B1 (en) * | 1999-12-10 | 2002-02-26 | American Home Products Corporation | Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
| US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
| US6599532B2 (en) * | 2000-01-13 | 2003-07-29 | Osmotica Corp. | Osmotic device containing alprazolam and an antipsychotic agent |
| US20020061339A1 (en) * | 2000-09-28 | 2002-05-23 | Martin Stogniew | Compositions and methods for use of extracts of rutaceae plants |
| US20050054942A1 (en) * | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
| MXPA03006003A (es) * | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
| US7053092B2 (en) * | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| JP2004518699A (ja) * | 2001-02-06 | 2004-06-24 | アストラゼネカ・アクチエボラーグ | クエチアピンを用いた物質乱用の治療方法 |
| US20020123490A1 (en) * | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
| US20030109546A1 (en) * | 2001-04-26 | 2003-06-12 | Fenton Wayne S. | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
| US6621096B2 (en) * | 2001-05-21 | 2003-09-16 | Hewlett-Packard Develpoment Company, L.P. | Device isolation process flow for ARS system |
| CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| DE60234873D1 (de) * | 2001-06-19 | 2010-02-04 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen |
| DE10129320A1 (de) * | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| EP1408981B1 (en) * | 2001-07-23 | 2008-08-27 | Corcept Therapeutics, Inc. | Methods for preventing antipsychotic-induced weight gain |
| US7544681B2 (en) * | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| GB0202900D0 (en) * | 2002-02-07 | 2002-03-27 | Laxdale Ltd | Novel formulations of drugs |
| US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| CA2494109A1 (en) * | 2002-07-29 | 2004-02-05 | Potomac, Pharma, Llc. | Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| MXPA05000294A (es) * | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| EP1589974A2 (en) * | 2003-01-23 | 2005-11-02 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| US20050250767A1 (en) * | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| CA2525366A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| US20050171139A1 (en) * | 2003-10-07 | 2005-08-04 | Hammer Ronald P.Jr. | Treating psychotic symptoms |
| JP2007509155A (ja) * | 2003-10-21 | 2007-04-12 | アルファーマ インコーポレイテッド | クエチアピンを含有する薬剤 |
| US7884096B2 (en) * | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| PL1696931T3 (pl) * | 2003-12-22 | 2009-10-30 | Acadia Pharm Inc | Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych |
| EP1699488A2 (en) * | 2003-12-23 | 2006-09-13 | Pfizer Products Incorporated | Therapeutic combination for cognition enhancement and psychotic disorders |
| BRPI0507250A (pt) * | 2004-01-29 | 2007-06-26 | Pfizer Prod Inc | combinações para tratar desordens do snc |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| EP1718311A1 (en) * | 2004-02-13 | 2006-11-08 | Pfizer Products Incorporated | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |
| US20050181071A1 (en) * | 2004-02-18 | 2005-08-18 | Binder Michael R. | Method for the treatment of clinical depression |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| WO2005102366A2 (en) * | 2004-04-19 | 2005-11-03 | Philip Maxwell Satow | Lithium combinations, and uses related thereto |
| JP2007537232A (ja) * | 2004-05-11 | 2007-12-20 | ファイザー・プロダクツ・インク | 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ |
| US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US8285900B2 (en) * | 2009-02-17 | 2012-10-09 | The Board Of Regents Of The University Of Texas System | Method and apparatus for congestion-aware routing in a computer interconnection network |
-
2005
- 2005-01-26 US US11/043,622 patent/US20050171088A1/en not_active Abandoned
- 2005-01-27 EP EP05704762A patent/EP1713488A1/en not_active Withdrawn
- 2005-01-27 KR KR1020067015308A patent/KR20070011276A/ko not_active Withdrawn
- 2005-01-27 CN CNA2005800036905A patent/CN1913902A/zh active Pending
- 2005-01-27 BR BRPI0507086-4A patent/BRPI0507086A/pt not_active IP Right Cessation
- 2005-01-27 RU RU2006130687/14A patent/RU2006130687A/ru not_active Application Discontinuation
- 2005-01-27 AU AU2005209142A patent/AU2005209142A1/en not_active Abandoned
- 2005-01-27 WO PCT/SE2005/000094 patent/WO2005072742A1/en not_active Ceased
- 2005-01-27 JP JP2006550998A patent/JP2007520488A/ja active Pending
- 2005-01-28 CA CA002495361A patent/CA2495361A1/en not_active Abandoned
-
2006
- 2006-07-20 IL IL176999A patent/IL176999A0/en unknown
- 2006-07-24 ZA ZA200606128A patent/ZA200606128B/xx unknown
- 2006-08-29 NO NO20063856A patent/NO20063856L/no not_active Application Discontinuation
-
2010
- 2010-08-17 US US12/857,897 patent/US20100311718A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005209142A1 (en) | 2005-08-11 |
| US20050171088A1 (en) | 2005-08-04 |
| RU2006130687A (ru) | 2008-03-10 |
| EP1713488A1 (en) | 2006-10-25 |
| ZA200606128B (en) | 2007-11-28 |
| CN1913902A (zh) | 2007-02-14 |
| BRPI0507086A (pt) | 2007-06-19 |
| KR20070011276A (ko) | 2007-01-24 |
| IL176999A0 (en) | 2006-12-10 |
| WO2005072742A1 (en) | 2005-08-11 |
| CA2495361A1 (en) | 2005-07-30 |
| US20100311718A1 (en) | 2010-12-09 |
| NO20063856L (no) | 2006-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100311718A1 (en) | Treatment of Psychoses with Dibenzothiazepine Antipsychotic | |
| JP3984787B2 (ja) | 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用 | |
| JP2006506378A5 (enExample) | ||
| WO2014052935A2 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| KR20010015918A (ko) | 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드 | |
| AU2004241110A1 (en) | Pharmaceutical combination comprising modafinil and another drug | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2007520488A5 (enExample) | ||
| JPWO2008090736A1 (ja) | アルツハイマー型認知症の予防及び治療のための医薬 | |
| PT1628652E (pt) | Combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão | |
| ES2275619T3 (es) | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. | |
| Kazamatsuri et al. | Treatment of tardive dyskinesia: III. Clinical efficacy of a dopamine competing agent, methyldopa | |
| US11628151B2 (en) | N,N-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases | |
| RU2369393C2 (ru) | Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна | |
| MXPA06008131A (en) | Treatment of psychoses with quetiapine antipsychotic | |
| JPWO2021087432A5 (enExample) | ||
| JP2004508333A (ja) | クエチアピンの新規な用途 | |
| EP4205738A1 (en) | Application of sesquiterpene lactone in preparing drug for treating optic neuritis | |
| JP2024541770A (ja) | 神経障害の治療方法 | |
| JP2022071083A (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| Jeste et al. | Tardive Dyskinesia: A Review of the Treatment Possibilities | |
| JPWO2020018291A5 (enExample) | ||
| McQuade et al. | haloperidol with placebo in acutely agitated schizophrenia patients | |
| Bowden et al. | Risperidone treatment for acute mania: assessment of tolerability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080118 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110419 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111011 |